By encouraging more providers to take on risk faster, the current administration may actually be disincentivizing providers from participating at all, which would reduce the number of accountable care organizations (ACOs), said Allison Brennan, MPP, senior vice president of government affairs for the National Association of ACOs.
By encouraging more providers to take on risk faster, the current administration may actually be disincentivizing providers from participating at all, which would reduce the number of accountable care organizations (ACOs), said Allison Brennan, MPP, senior vice president of government affairs for the National Association of ACOs.
Transcript
In what ways has the current administration encouraged or discouraged providers from taking on more risk?
The current administration is definitely encouraging providers to assume more accountability in the form of risk. We’ve seen this in a number of difference ways. There really is an emphasis to assume risk more quickly, and that’s something that I think we’re troubled by, but they view increased accountability as one of the main ways to reduce costs. I think we’re pushing back on that notion because we see a lot of really great work being done by our members to reduce costs and improve quality before they’re in a risk-based model.
One thing I would also note is that I think in a way the current administration has discouraged moving to risk by proposing to make the pipeline for ACOs, sort of, diminished. So, if we have fewer ACOs that are incentivized to enter the program, I think long term we’ll see fewer ACOs that are ready to take on risk.
So, it’s sort of a little bit of a catch 22: by pushing people into risk too fast, you may actually disincentivize them from participating at all.
Late-Breaking Antiviral Session Features Phase 3 Results on Efficacy of Doravirine/Islatravir
March 13th 2025The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access
March 12th 2025Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.
Read More